Added to YB: 2026-06-19
Pitch date: 2026-06-17
LQDA [neutral]
Liquidia Corporation
+19.41%
current return
Author Info
Value with a Catalyst covers long value oriented small and mid- cap investment ideas with a catalyst. Sign up for the newsletter.
Company Info
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for rare cardiopulmonary diseases in the United States.
Market Cap
$7.1B
Pitch Price
$70.44
Price Target
172.00 (+98%)
Dividend
N/A
EV/EBITDA
147.57
P/E
327.46
EV/Sales
24.55
Sector
Pharmaceuticals
Category
growth
Liquidia - Near-Term Market Expansion Prospects
LQDA (update): $6B mkt cap vs UTHR $24B. Yutrepia best-in-class inhaled prostacyclin, 25% head-to-head share (5.5% of PAH). 2x share floor likely w/ salesforce expansion. PAH: 2.5x oral-displacement upside; PH-ILD: 10x as only 10% treated, but UTHR patent dispute risk (author expects win post-Hikma).
Read full article (3 min)